[{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Df1001","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Dragonfly Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"DF6002","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DF6002","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"DF6002","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ABBV-303","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dragonfly Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Expanded Collaboration","leadProduct":"MK-4464","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Dragonfly Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"DF6215","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"DF9001","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"DF7001","moa":"5T4 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Dragonfly Therapeutics \/ Gilead Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by Dragonfly Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : Through the collaboration, DF9001 Dragonfly's EGFR immune engager, in combination with Merck's anti-PD-1 therapy, Keytruda in patients with advanced solid tumors.

                          Product Name : DF9001

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          May 21, 2024

                          Lead Product(s) : DF9001,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : The collaboration aims to focus on the development of ABBV-303 in combination with ABBV-181, which is being evaluated in the Phase I clinical trial studies for the treatment of neoplasms.

                          Product Name : ABBV-303

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 03, 2024

                          Lead Product(s) : ABBV-303,Budigalimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : AbbVie Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : The collaboration aims to combine DF1001, targeting NK cells and T-cell activation, with Gilead's Trop-2 antibody-drug conjugate for treating breast and lung cancers.

                          Product Name : DF1001

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 15, 2024

                          Lead Product(s) : Df1001,Sacituzumab Govitecan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : DF6002 is a monovalent IL12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses.

                          Product Name : DF6002

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 02, 2023

                          Lead Product(s) : DF6002,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : Dragonfly lead product candidate DF6215, which is IL-2 Immunotherapy. Currently, it is being evaluated in the clinical development with patients for the treatment of advanced solid tumors.

                          Product Name : DF6215

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          May 12, 2023

                          Lead Product(s) : DF6215

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : The Company’s first TriNKET, DF1001, entered Phase 2 trials this month after being well-tolerated in Phase 1 with encouraging clinical responses, including showing tumor burden reductions across several tumor types, including in HER2-low and heavily pr...

                          Product Name : DF1001

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          August 12, 2022

                          Lead Product(s) : Df1001,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : DF1001 was well-tolerated with no dose limiting toxicities during dose escalation in the Phase 1 study. The study showed encouraging pharmacodynamic effects including infiltration of NK cells and T cells into tumors.

                          Product Name : DF1001

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 12, 2022

                          Lead Product(s) : Df1001,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : Under the agreement, Gilead will receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy, DF7001. Gilead also gains worldwide rights to develop and commercialize NK cell engager programs using the Dragon...

                          Product Name : DF7001

                          Product Type : Cell and Gene therapy

                          Upfront Cash : $300.0 million

                          February 05, 2022

                          Lead Product(s) : DF7001

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : Under the agreement Merck has exercised its option to license exclusive worldwide intellectual property rights on its second immunotherapy candidate DF8001 (MK-4464), developed using the TriNKET™ technology platform.

                          Product Name : DF8001

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          January 11, 2022

                          Lead Product(s) : MK-4464,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          10

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : DF6002/BMS-9896415, a monovalent IL-12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses.

                          Product Name : DF6002

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 03, 2022

                          Lead Product(s) : DF6002,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank